[Treatment of adenosine deaminase deficiency with adenosine deaminase combined with polyethylene glycol]. 1992

D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
Unité d'Immuno-Hématologie, INSERM U132, Hôpital des Enfants-Malades, Paris.

Adenosine deaminase (ADA) deficiency is one the causes of severe combined immunodeficiency syndrome. Treatment was, until now, based on bone marrow transplantation. HLA identical bone marrow transplantation yields excellent results while those of HLA haploidentical bone marrow transplantation are not so good. A new therapeutic approach was developed recently, consisting of the intramuscular infusion of ADA enzyme covalently linked to polyethylene glycol (PEG-ADA). We report the results of this treatment in a 14 month-old child presenting with a partial form of ADA deficiency revealed by an opportunistic infection. This treatment corrected the immunodeficiency and the biochemical abnormalities as well. PEG-ADA infusions were well tolerated. The onset of an immunization against the ADA enzyme led to a drop in immunologic functions, which could be partially overcome by more frequent (biweekly) administration of the product. After a 18 month-follow-up the child is doing well, living normally at home. PEG-ADA represents a possible alternative for children presenting with ADA deficiency without any available HLA identical donor.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000243 Adenosine Deaminase An enzyme that catalyzes the hydrolysis of ADENOSINE to INOSINE with the elimination of AMMONIA. Adenosine Aminohydrolase,Aminohydrolase, Adenosine,Deaminase, Adenosine
D016511 Severe Combined Immunodeficiency Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID). Bare Lymphocyte Syndrome,Immunodeficiency, Severe Combined,Omenn Syndrome,Immunodeficiency Syndrome, Severe Combined,Immunologic Deficiency, Severe Combined,Omenn's Syndrome,Reticuloendotheliosis, Familial,Severe Combined Immune Deficiency,Severe Combined Immunodeficiency Syndrome,Severe Combined Immunologic Deficiency,Bare Lymphocyte Syndromes,Combined Immunodeficiencies, Severe,Combined Immunodeficiency, Severe,Familial Reticuloendothelioses,Familial Reticuloendotheliosis,Immunodeficiencies, Severe Combined,Lymphocyte Syndrome, Bare,Lymphocyte Syndromes, Bare,Omenns Syndrome,Reticuloendothelioses, Familial,Severe Combined Immunodeficiencies,Syndrome, Bare Lymphocyte,Syndrome, Omenn,Syndrome, Omenn's,Syndromes, Bare Lymphocyte

Related Publications

D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
March 1987, The New England journal of medicine,
D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
August 1993, The Journal of clinical investigation,
D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
July 2007, The Journal of pediatrics,
D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
August 1988, The Journal of pediatrics,
D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
January 1993, Immunodeficiency,
D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
May 1992, The Journal of clinical investigation,
D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
April 1998, The Journal of allergy and clinical immunology,
D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
December 2005, Pediatrics,
D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
March 2003, Biochimica et biophysica acta,
D Girault, and F Le Deist, and M Debré, and J L Pérignon, and C Herbelin, and C Griscelli, and D Sciudery, and M Hershfield, and A Fischer
October 2009, The Journal of allergy and clinical immunology,
Copied contents to your clipboard!